Achieve Life Sciences is a late-stage clinical pharmaceutical company developing cytisinicline, a naturally occurring alkaloid, as a treatment for smoking and e-cigarette cessation. The company is pursuing regulatory approval in the United States for a novel smoking cessation medicine with demonstrated clinical efficacy and a favorable safety profile, with plans to commercialize through partnerships and multiple distribution channels. Achieve operates under exclusive development and commercialization rights outside Central and Eastern Europe, leveraging decades of international market experience with the compound and a proprietary patent portfolio, with revenue anticipated from prescription product sales upon market approval.